ArticleClinical genitourinary cancer2016
Clinical Significance of p53 and p16(ink4a) Status in a Contemporary North American Penile Carcinoma Cohort.
Article in Clinical genitourinary cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Prognostic Significance of P16BioMed research international · 2018Pooled it
- From biology to morphology and treatment: the current role of pathology in penile cancer - a narrative review.Frontiers in oncology · 2026Review
- Low GATA3 predicts worse survival in penile cancer.Scientific reports · 2025Article
- Treatment strategies in human papillomavirus-related advanced penile cancer.Nature reviews. Urology · 2025Review
- A review of the carcinogenic potential of human papillomavirus (HPV) in urological cancers.Virology journal · 2025Review
- Multiplex Immunofluorescence Captures Progressive Immune Exhaustion with Advancing Penile Squamous Cell Cancer Stage.Cancers · 2024Article
- The Prognostic Role of Human Papillomavirus and p16 Status in Penile Squamous Cell Carcinoma-A Systematic Review.Cancers · 2023Review
- P53 in Penile Squamous Cell Carcinoma: A Pattern-Based Immunohistochemical Framework with Molecular Correlation.Cancers · 2023Article
- Prognostic Markers and Trials in Penile Cancer.Urology research & practice · 2023Article
- A comprehensive analysis of penile cancer in the region with the highest worldwide incidence reveals new insights into the disease.BMC cancer · 2022Article
- The dual pathogenesis of penile neoplasia: The heterogeneous morphology of human papillomavirus-related tumors.Asian journal of urology · 2022Review
- A global approach to improving penile cancer care.Nature reviews. Urology · 2022Review
- A systematic review of non-HPV prognostic biomarkers used in penile squamous cell carcinoma.Turkish journal of urology · 2021Article
- The Immune Microenvironment in Penile Cancer and Rationale for Immunotherapy.Journal of clinical medicine · 2020Review
- Understanding genomics and the immune environment of penile cancer to improve therapy.Nature reviews. Urology · 2020Review
- Presence of HPV with overexpression of p16INK4a protein and EBV infection in penile cancer-A series of cases from Brazil Amazon.PloS one · 2020Article
- Tumor Microenvironment in Penile Cancer.Advances in experimental medicine and biology · 2020Review
- Paving the way for more precise diagnosis of EcPV2-associated equine penile lesions.BMC veterinary research · 2019Article
- P53 and Survival Rate in Penile Cancer.Open access Macedonian journal of medical sciences · 2019Article
- Impact of PI3K-AKT-mTOR Signaling Pathway Up-regulation on Prognosis of Penile Squamous-Cell Carcinoma: Results From a Tissue Microarray Study and Review of the Literature.Clinical genitourinary cancer · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
backgroundBecause of the low incidence of penile carcinoma (PC), the value of p16(ink4a), p53, and human papilloma virus (HPV) infection status in clinical practice remains unclear. Herein, we report our experience with potential clinical utility of these markers in men with PC treated at our institution. PATIENTS AND
methodsTissue microarrays of 57 cases of invasive penile squamous cell carcinomas were immunohistochemically stained for p16 and p53. HPV in situ hybridization (ISH) for high-risk subtypes was also performed. Association between marker status, nodal disease, overall (OS) and cancer-specific survival (CSS) were assessed.
resultsp16 and HPV ISH were positive in 23 (40%) and 24 (42%) of the cohort, respectively. The proportion of warty, basaloid, or mixed warty basaloid tumor subtypes were significantly greater in the p16-positive patients (48% vs. 3%; P < .01). p53 expression was negative in 31 (54%) cases. Only in p16-negative patients, positive p53 status was associated with pN+ disease (odds ratio, 4.4 [95% confidence interval (CI), 1.04-18.6]). In Kaplan-Meier analysis, the unadjusted estimated OS was insignificantly longer in p16-positive patients (median OS, 75 vs. 27 months; P = .27) and median CSS was not reached (P = .16). In a multivariable Cox proportional hazard model, when controlling for pathological nodal status and adjuvant chemotherapy, p16 status was a significant predictor for improved CSS (hazard ratio, 0.36 [95% CI, 0.13-0.99]). The worst CSS was seen in pN+ patients with double negative p16 and p53 expression (8 vs. 34 months; P = .01).
conclusionIn this current cohort, p53 and p16 status showed clinical utility in predicting nodal disease as well as survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.